Safety and side effect profile of fluoxetine
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders. Its attributes have been described in numerous scientific papers, and it has been the subject of a considerable volume of lay press. Fluoxetine is generally safe and well-tolerated. Common adverse events reported with the recommended dose of 20 mg/day are referable to the gastrointestinal system and the nervous system. The approved dose range is up to 80 mg/day, and when higher doses are used, adverse events are more common. The long half-life of fluoxetine and its active metabolite essentially preclude a withdrawal phenomenon. It is an inhibitor of cytochrome P450 (CYP) 2D6 and other CYP enzymes, which increases the potential for drug interactions. However, most of these are not clinically important. The purpose of this review is to provide an overview of some of the most important information related to safety and side effects of this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Sauer, W. H., Berlin, J. A., & Kimmel, S. E. (2003) · Circulation · doi:10.1161/01.cir.0000079172.43229.cd · Cited by 247 · cited 1×
“Fluoxetine, like other SSRIs, may actually decrease the risk of myocardial infarction due to its serotonin-depleting effect on platelets [73].”
BackgroundAntidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Reimherr, F. W., Amsterdam, J. D., Quitkin, F. M., Rosenbaum, J. F., Fava, M., Zajecka, J., Beasley, Jr., Michelson, D., Roback, P., & Sundell, K. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1247 · Cited by 204
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181 · cited 1×
“Five-day interruption of fluoxetine treatment was found not to be associated with the emergence of adverse events [104].”
BackgroundSafety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study
Zajecka, J., Fawcett, J., Amsterdam, J., Quitkin, F., Reimherr, F., Rosenbaum, J., Michelson, D., & Beasley, C. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199806000-00003 · Cited by 85
Fluoxetine Pharmacokinetics in Pediatric Patients
Wilens, T. E., Cohen, L., Biederman, J., Abrams, A., Neft, D., Faird, N., & Sinha, V. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200212000-00006 · Cited by 64 · cited 1×
“1 Children and adolescents Children develop steady-state plasma concentrations of fluoxetine and norfluoxetine that are approximately twice those of adolescents, whose pharmacokinetic parameters are similar to those of adults [57].”
BackgroundTreatment Approaches to Major Depressive Disorder Relapse
Schmidt, M. E., Fava, M., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063643 · Cited by 60
Blood Pressure Changes During Short-Term Fluoxetine Treatment
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., & Beasley, C. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00004 · Cited by 51
Cited by
The Discovery of Fluoxetine Hydrochloride (Prozac)
Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1821 · Cited by 418
Ketamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
Cancer and stress: NextGen strategies
Cui, B., Peng, F., Lu, J., He, B., Su, Q., Luo, H., Deng, Z., Jiang, T., Su, K., Huang, Y., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.005 · Cited by 152
“Moreover, for many cancer patients, fluoxetine plays a critical role in relieving depression, but it also causes insomnia and anxiety in some of them (Wernicke, 2004).”
Detke, H. C., DelBello, M. P., Landry, J., & Usher, R. W. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.012 · Cited by 135
Metadata
- Authors
- Wernicke, J. F.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2004-09
- Volume
- 3
- Issue
- 5
- Pages
- 495-504
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W1996529676
- Cited by
- 52
- References
- 10
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.